C
코미팜
041960KOSDAQ의약품 제조업48.0 / 100
Reference Date: 2026-04-13
Financial Score12.5 / 40
News Sentiment12.5 / 25
Momentum11.0 / 20
Disclosure12.0 / 15
AI Analysis: ROE is below the industry average, PBR raises overvaluation concerns. Slightly up 1.9% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Komipharm is a company established in 1972 specializing in the production and sale of animal vaccines and pharmaceuticals, with key products including ASF vaccines and Pro-vacTM PED-Fc. It is actively expanding globally through the development of cancer treatment drug PAX-1. In 2024, sales increased by 38% year-on-year to 58.8 billion won, with operating profit from animal pharmaceuticals reaching 89.77 billion won.
Number of Employees
172people
Average Salary
47.1M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 14.804.0Point
PBR
8.62Industry Average 1.040.0Point
8.3x industry avg (risky)
ROE
-11.67Industry Average 4.420.0Point
Well below industry avg
Debt Ratio
12.64Industry Average 11.982.0Point
Higher than industry avg (caution)
Trend 2023~20256.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲13.5% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲65.2% (2-year basis)
ROE Trend
1.0 / 4
Avg ROE 0.8% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position6.0Point
52w upper range (75%)
Current 8,410Won52-week high 9,61052-week low 4,765
1-month return3.0Point
1m 1.94% (flat)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
5 totalPositive 1Neutral 4Negative 0
- Positive[기재정정]단일판매ㆍ공급계약체결2026-04-08
- Neutral정기주주총회결과2026-03-26
- Neutral주식매수선택권부여에관한신고2026-03-26
- Neutral사업보고서 (2025.12)2026-03-18
- Neutral감사보고서제출2026-03-18